Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Liabilities (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Total Liabilities for 12 consecutive years, with $50.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 68.69% year-over-year to $50.9 million, compared with a TTM value of $50.9 million through Sep 2025, down 68.69%, and an annual FY2024 reading of $121.0 million, down 51.46% over the prior year.
  • Total Liabilities was $50.9 million for Q3 2025 at CytomX Therapeutics, down from $55.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $353.5 million in Q1 2021 and bottomed at $50.9 million in Q3 2025.
  • Average Total Liabilities over 5 years is $246.3 million, with a median of $294.2 million recorded in 2023.
  • The sharpest move saw Total Liabilities grew 4.18% in 2021, then tumbled 71.04% in 2025.
  • Year by year, Total Liabilities stood at $339.9 million in 2021, then increased by 1.99% to $346.6 million in 2022, then fell by 28.1% to $249.2 million in 2023, then plummeted by 51.46% to $121.0 million in 2024, then tumbled by 57.96% to $50.9 million in 2025.
  • Business Quant data shows Total Liabilities for CTMX at $50.9 million in Q3 2025, $55.1 million in Q2 2025, and $73.4 million in Q1 2025.